Afternoon Market Losers

plunged 14.63% to $10.21 amid a Phase 3 trial of Arikace which met a primary endpoint, but a company slideshow which revealed competitor Novartis's

Tobi drug showed more favorable results.

dropped 12.83% to $38.92 after the company lost 1st round of case against ZTE, Huawei, and Nokia.

tumbled 12.54% to $2.65 after the company announced that the company had been added to the 2013 Russell 3000® Index.

dropped 9.88% to $29.37 after the company split its business into two companies.

dipped 10.78% to $1.40.

traded down 3.40% to $32.10 after the company filed to sell 7 million ordinary shares for holders.

dropped 13.91% to $1.98 after the company completed its merger with Lexington Technology Group.